NEW YORK, March 15 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX)
International VRX.TO said on Tuesday that it was making
changes to the way it accounts its tax rate at the suggestion of
the Securities and Exchange Commission.
Valeant CEO Michael Pearson (LON:PSON) said during an analyst
conference call that the SEC had made the suggestion as part of
regular communication and that it was not part of an
investigation into the company. It will result in the
presentation of a higher tax rate, but no change to cash flow,
he said.